



8TH ANNUAL REPORT 2023-24

ASSAM MEDICAL SERVICES CORPORATION LIMITED

(A Govt. of Assam undertaking)

CIN: U85204AS2014SG001746 I

Email: assam.mscl@gmail.com

Website: www.amsclassam.gov.in



TABLE OF CONTENTS

❖ CORPORATE INFORMATION	3
❖ NOTICE OF THE 8 TH ANNUAL GENERAL MEETING	4
❖ NOTICE OF THE ADJOURNED 8 TH ANNUAL GENERAL MEETING	7
❖ DIRECTORS' REPORT	11
❖ COMMENTS OF THE C&AG	20
❖ STATUTORY AUDITORS REPORT	24
❖ FINANCIAL STATEMENT FOR THE YEAR ENDED 31 ST MARCH, 2024.....	36

CORPORATE INFORMATION



Assam Medical Services Corporation Limited

CIN: U85320AS2016SGC017461

Registered Office: Central Drug Warehouse, Patharquary, Narengi, Guwahati-781029, Assam

Assam Medical Services Corporation (AMSC) was incorporated under the Companies Act 2013 on 22nd June, 2016.

Date of Incorporation: 22/06/2016

Authorized Share Capital: Rs. 15,00,00,000/-

Paid up Share Capital: Rs. 8,54,00,000/-

Board of Directors as on 31.03.2024

The primary objective of AMSC is to act as the central procurement agency for procuring essential drugs, surgical consumables, equipments etc. on behalf of all the Directorates under Health & Family Welfare Department, Government of Assam, National Health Mission, Assam and National AYUSH Mission, Assam. This objective extends to any other directorate/body/ agency/mission that may be created under the Health & Family Welfare Department in future.

Shri. Patibandia Ashok Babu, IAS	Hon'ble Chairman
Dr. M. S. Lakshmi Priya, IAS	Director
Dr. Robin Kumar, IPS	Managing Director
Shri Niranjan Borah	Director
Dr. Anup Kumar Barman	Director

Statutory Auditor

M/s N. K. Choudhary & Associates., Chartered Accountants, 2nd Floor, Subhadra Bhawan, Opp. Christian Hospital, Chatrabari, Guwahati-781008, Assam

The procurement operations at AMSC commenced on 1st April, 2023.

Bankers State Bank of India HDFC Bank Limited

NOTICE OF THE 8TH ANNUAL GENERAL MEETING

NOTICE is hereby given that the eighth (8th) **Annual General Meeting** of the shareholders of **ASSAM MEDICAL SERVICES CORPORATION LIMITED** will be held on Monday, the 16th day of September, 2024 at 12:30 pm at the registered office of the Corporation at Central Drug Warehouse, Narengi, Guwahati - 781026, Assam to transact the following business as:

Ordinary Business:

1. To receive, consider and adopt the Audited Financial Statement of the Company for the financial year ended on 31st March, 2024 and the Reports of the Board of Directors and the Statutory Auditors and the Comments of the Comptroller & Auditor General of India thereon.
2. To fix the remuneration of the Statutory Auditors of the Company for the Financial Year 2024-25

**By Order of the Board of Directors of
M/s Assam Medical Services Corporation Limited**



**Robin Kumar, IPS
(Managing Director)
DIN: 09442400**

Date:
Place: Guwahati

Enclosed : 1. Proxy Form (Form MGT - 11)
 2. Attendance Slip

NOTES:

A MEMBER ENTITLED TO ATTEND AND VOTE IS ENTITLED TO APPOINT A PROXY TO ATTEND AND VOTE INSTEAD OF HIMSELF/HERSELF AND THE PROXY NEED NOT BE A MEMBER OF THE COMPANY. A BLANK PROXY FORM IS ENCLOSED WHICH, IF USED, SHOULD BE DEPOSITED WITH THE COMPANY DULY EXECUTED NOT LATER THAN 48 HOURS BEFORE THE COMMENCEMENT OF THE ANNUAL GENERAL MEETING.

Form No. MGT-11 PROXY FORM

(Pursuant to Section 105(6) of the Companies Act, 2013 and rules 19(3)
of the Companies (Management and Administration) Rules, 2014)

Name of the member (s): _____

Registered Address: _____

E.Mail Id: _____ Folio No. /Client Id _____ DP ID _____

I/We, being the member(s) holding _____ shares of the above named Company, hereby appoint

1. Name: _____ Address: _____

E.mail ID: _____ Signature _____

2. Name: _____ Address: _____

E.mail ID: _____ Signature _____

or failing him

3. Name: _____ Address: _____

E.mail ID: _____ Signature _____

as my/our proxy to attend and vote (on a poll) for me/us and on my/our behalf at the 8th Annual General Meeting of the Corporation, to be held on Monday, the 16th day of September, 2024 at 12:30 pm at the registered office of the Corporation at Central Drug Warehouse, Narengi, Guwahati – 781026, Assam in respect of such resolutions as are indicated below:

RESOLUTION(S)	VOTE	
	FOR	AGAINST
Ordinary Resolution:		
1. To receive, consider and adopt the audited Balance Sheet as at 31 st March, 2024 and the Profit & Loss Account for the year ended on that date and the report of the Directors' and the Auditors' thereon along with comments of the Comptroller and Auditor General of India.		
2. To fix the remuneration of the Statutory Auditors of the Company for the Financial Year 2024-25.		

Signed this.....day of2024

Signature of Shareholder

Signature of Proxy holder(s)

Affix
Revenue
Stamp

Note: This form of proxy in order to be effective should be duly completed and deposited at the Registered Office of the Company, not less than 48 hours before the commencement of the meeting.

ATTENDANCE SLIP

8TH ANNUAL GENERAL MEETING

Reg. Folio/DP & Client No:..... No .of Shares Held:.....

I certify that I am a registered Shareholder/Proxy for the registered shareholder of the Corporation. I hereby record my presence at the 8th Annual General Meeting of the Corporation at the registered office of the Corporation at Central Drug Warehouse, Narengi, Guwahati – 781026, Assam on Monday, the 16th day of September, 2024.

Member's Name :

Proxy's Name :

Member's/ Proxy's Signature

Note:

1. Please fill this attendance slip and hand it over at the entrance of the Hall.
2. Members/Proxy Holders/Authorised Representatives are requested to show their Photo ID Proof for attending the Meeting.
3. Authorized Representatives of Corporate members shall produce proper authorization issued in their favour.


NOTICE OF THE ADJOURNED 8TH ANNUAL GENERAL MEETING

NOTICE is hereby given that the **Adjourned Eighth (8th) Annual General Meeting** of the shareholders of **Assam Medical Services Corporation Limited** will be held at a shorter notice on **Wednesday, the 9th day of September, 2026 at 11.00 a.m.** at the **registered office of the Corporation at Central Drug Warehouse, Narengi, Guwahati - 781026, Assam** to transact the following business as:

Ordinary Business:

1. To receive, consider and adopt the Audited Financial Statement of the Company for the financial year ended on 31st March, 2024 and to approve the Comments of the Comptroller & Auditor General of India thereon.

**By Order of the Board of Directors of
Assam Medical Services Corporation Limited**


8/9/26

Date: 08.09.2026
Place: Guwahati

Dr. Subramoney Lakshmanan, IAS
(Managing Director)
DIN: 09009335

Enclosed: 1. Proxy Form (Form MGT - 11)
2. Attendance Slip

NOTES:

A MEMBER ENTITLED TO ATTEND AND VOTE IS ENTITLED TO APPOINT A PROXY TO ATTEND AND VOTE INSTEAD OF HIMSELF/HERSELF AND THE PROXY NEED NOT BE A MEMBER OF THE COMPANY. A BLANK PROXY FORM IS ENCLOSED WHICH, IF USED, SHOULD BE DEPOSITED WITH THE COMPANY DULY EXECUTED NOT LATER THAN 48 HOURS BEFORE THE COMMENCEMENT OF THE ANNUAL GENERAL MEETING.

Form No. MGT-11

PROXY FORM

(Pursuant to Section 105(6) of the Companies Act, 2013 and rules 19(3)
 of the Companies (Management and Administration) Rules, 2014)

Name of the member (s): _____

Registered Address: _____

E.Mail Id: _____ Folio No. /Client Id _____ DP ID _____

I/We, being the member(s) holding _____ shares of the above named Company, hereby appoint

1. Name: _____ Address: _____

E.mail ID: _____ Signature _____

2. Name: _____ Address: _____

E.mail ID: _____ Signature _____

or failing him

3. Name: _____ Address: _____

E.mail ID: _____ Signature _____

as my/our proxy to attend and vote (on a poll) for me/us and on my/our behalf at the Adjourned 8th Annual General Meeting of the Company, to be held at a shorter notice on Wednesday, the 9th day of September, 2026 at 11.00 am at the registered office of the Corporation at Central Drug Warehouse, Narengi, Guwahati – 781026, Assam in respect of such resolutions as are indicated below:

RESOLUTION(S)	VOTE	
	FOR	AGAINST
Ordinary Resolution: 1. To receive, consider and adopt the audited Balance Sheet as at 31 st March, 2024 and the Profit & Loss Account for the year ended on that date and to approve the comments of the Comptroller and Auditor General of India.		

Signed this.....day of2026

Signature of Shareholder

Signature of Proxy holder(s)

Affix
 Revenue
 Stamp

Note: This form of proxy in order to be effective should be duly completed and deposited at the Registered Office of the Company, not less than 48 hours before the commencement of the meeting.

ATTENDANCE SLIP

ADJOURNED 8TH ANNUAL GENERAL MEETING

Reg. Folio/DP & Client No:..... No .of Shares Held:.....

I certify that I am a registered Shareholder/Proxy for the registered shareholder of the Corporation. I hereby record my presence at the Adjourned 8th Annual General Meeting of the Corporation at the registered office of the Corporation at Central Drug Warehouse, Narengi, Guwahati – 781026, Assam on at a shorter notice on Wednesday, the 9th day of September, 2026 at 11.00 a.m.

Member's Name :

Proxy's Name :

Member's/ Proxy's Signature

Note:

1. Please fill this attendance slip and hand it over at the entrance of the Hall.
2. Members/Proxy Holders/Authorised Representatives are requested to show their Photo ID Proof for attending the Meeting.
3. Authorized Representatives of Corporate members shall produce proper authorization issued in their favour.

EXPLANATORY NOTE ON COMPANIES COMPLIANCE FACILITATION SCHEME, 2026 (CCFS-2026)

The Ministry of Corporate Affairs (MCA), Government of India, has introduced the Companies Compliance Facilitation Scheme, 2026 (CCFS-2026) vide General Circular No. 01/2026 dated 24th February, 2026. The Scheme was effective from 15th April, 2026 and further extended via circular no 04/2026 to 15th day of September, 2026 and provides a one-time opportunity to companies to regularize pending statutory filings under the Companies Act, 2013 at substantially reduced additional fees.

Assam Medical Services Corporation Limited has pending statutory filings under the Companies Act, 2013. The Financial Statements for the financial year 2023-24 have been duly prepared and audited by the Statutory Auditors, and the respective Statutory Audit Reports have been received by the Company. The comments of the Comptroller and Auditor General of India (C&AG) under Section 143(6) of the Companies Act, 2013, which were earlier awaited, have now been received by the Company as on dated 19th August, 2026 for the aforesaid financial years.

Accordingly, the Audited Financial Statements for the financial years ended 31st March, 2024 are proposed to be placed before the members at the respective Adjourned Annual General Meeting to be held on Wednesday, the 9th day of September, 2026.

The convening of the Adjourned Annual General Meeting and consideration of the Financial Statements at this stage is being undertaken to facilitate compliance with the requirements of the Companies Act, 2013 and to enable the Company to avail the benefits of the Companies Compliance Facilitation Scheme, 2026. Since the last date for availing the benefits of the said Scheme is 15th September, 2026, and the Adjourned 8th Annual General Meeting is required to be convened and concluded on or before the said date, the members are accordingly requested to accord their consent for holding the Adjourned Annual General Meeting at shorter notice. Upon receipt of the comments of the Comptroller and Auditor General of India, if any, the same shall be placed before the shareholders and necessary action shall be taken in accordance with the provisions of the Companies Act, 2013.

The Board of Directors recommends that the members take note of the above circumstances while considering the business set out in the Notice.

DIRECTORS' REPORT

To,
The Members,
Assam Medical Services Corporation Limited
(CIN: U85320AS2016SGC017461)
Central Drug Warehouse, Narengi,
Guwahati-781026

Your Directors have pleasure in presenting their eighth (8th) Annual Report on the business and operations of the Corporation "ASSAM MEDICAL SERVICES CORPORATION LIMITED" for the Financial Year ended 31st March, 2024.

1. FINANCIAL SUMMARY OR HIGHLIGHTS/ PERFORMANCE OF THE CORPORATION:

The summary of financial results for the year ended on 31st March, 2024 is summarized below:

Particulars	2023-24 (Rs. in Lakhs)	2022-23 (Rs. in Lakhs)
Revenue from Operations	1,452.96	0.00
Other Income	71.31	8.71
Total Income	1,524.27	8.71
Less: Total Expenses	525.09	197.01
Profit Before Tax	999.18	(188.30)
Less: (i) Current Tax	214.00	0.00
(ii) Deferred Tax	(0.17)	7.92
Profit /Loss for the year	785.35	(196.22)

2. BRIEF DESCRIPTION OF THE CORPORATION'S WORKING DURING THE YEAR/ STATE OF CORPORATION'S AFFAIR:

During FY 2023-24, AMSCL recorded a significant improvement in its financial performance, reporting total income of Rs. 1,524.27 lakh compared to Rs. 8.71 lakh in the previous year. The revenue from operations of Rs. 1,452.96 lakh was primarily attributable to service charges earned for the procurement of drugs and medical equipment on behalf of the Government of Assam. Total expenses stood at Rs. 525.09 lakh, resulting in a Profit Before Tax of Rs. 999.18 lakh as against a loss before tax of Rs. 188.30 lakh in FY 2022-23. After providing for current tax of Rs. 214.00 lakh and accounting for deferred tax, the Company reported a Profit After Tax of Rs.

785.35 lakh, marking a substantial turnaround from the loss of Rs. 196.22 lakh incurred in the previous financial year.

3. DETAILS REGARDING AMOUNT TO BE TRANSFERRED TO THE RESERVES:

The profit earned during the financial year has been transferred to the Reserves and Surplus account and has been adjusted against the accumulated losses of the Company, thereby strengthening its financial position.

4. DIVIDEND:

Your directors do not recommend dividend on the shares of the Corporation for the financial year under review.

5. SHARE CAPITAL:

The Authorized Share Capital of the Corporation is Rs. 15,00,00,000/- divided into 15,00,000 equity shares of Rs. 100/- each.

The issued and subscribed share capital of the Corporation is Rs. 8,54,00,000/- divided into 8,54,000 equity shares of Rs. 100/- each..

The paid-share capital of the Corporation as at 31st March, 2024 is Rs. 8,54,00,000/- divided into 8,54,000 equity shares of Rs. 100/- each.

6. COMPOSITION OF BOARD OF DIRECTORS:

During the year under review, Shri. Avinash P Joshi, IAS ceased to be Chairman of the Corporation w.e.f 16/01/2024 pursuant to his transfer from the Additional Chief Secretary to the Govt. of Assam, Health & Family Welfare Department and Dr. Patibandla Ashok Babu, IAS was appointed as the Chairman of the Corporation by the virtue of his posting as the Commissioner & Secretary to the Govt of Assam, Health and Family Welfare Department.

Further, Smti Pranati Majumdar, ACS was transferred from the Health & Family Welfare Department to Agriculture Department pursuant to Govt. of Assam Notification, as such she relieved from the position of Additional Managing Director of the Corporation on 13/03/2024.

The composition of the Board of Director as on 31.03.2024 is:

Sl. No.	Name	Designation	Date of Appointment	Date of Cessation (if any after the end of financial year)
1	Dr. Patibandla Ashok Babu, IAS	Hon'ble Chairman	16/01/2024	NA
2	Dr. M. S. Lakshmi Priya, IAS	Director	20/07/2022	21/08/2024
3	Dr. Robin Kumar, IPS	Managing Director	22/10/2021	09/09/2025

4	Shri Niranjan Borah	Director	17/11/2022	28/04/2024
5	Dr. Anup Kumar Barman	Director	22/06/2016	23/02/2026

7. **BOARD MEETINGS:**

During the Financial Year 2023-24, three (3) Board Meetings were held on following dates:-

No. of Board meetings held	Date of Board meeting
25 th Board Meeting	31/05/2023
26 th Board Meeting	20/09/2023
27 th Board Meeting	10/01/2024

Attendance of Directors in the Board Meetings held during the Financial Year ended 2023-24:

Sl. No.	Name of the Director	Attendance		
		No. of Board meeting entitled to attend	No. of Board meeting attended	%
1	Dr. Patibandla Ashok Babu, IAS	0	0	NA
2	Dr. M. S. Lakshmi Priya, IAS	3	0	0
3	Dr. Robin Kumar, IPS	3	3	100
4	Shri Niranjan Borah	3	0	0
5	Dr. Anup Kumar Barman	3	3	100

Percentage computed by considering the meetings attended with the total meetings entitled to attend during the financial year under review.

8. **DISCLOSURE OF INTEREST BY DIRECTOR:**

Your Directors has followed the Corporate Ethics and under Section 184(1) of the Companies Act, 2013 has given the notice to the Corporation disclosing their interest in companies and firm in which they are interested or concerned.

9. **POLICY ON DIRECTOR'S APPOINTMENT AND REMUNERATION AND OTHER COMMITTEES IN EXISTENCE IN THE CORPORATION UNDER SUB SECTION (1) OF SECTION 178:**

The Corporation has no Audit Committee, Nomination & Remuneration Committee in existence as it is not applicable to the Corporation. Being a State Government Corporation, the matters relating to the appointment and remuneration of the Director are taken care by the Government of Assam.

10. STATEMENT ON COMPLIANCE OF APPLICABLE SECRETERIAL STANDARDS:

The Corporation has complied with the Secretarial Standards issued by the Institute of Company Secretaries of India (ICSI), as applicable to meetings of the Board of Directors and General Meetings, except that only three Board Meetings were held during the year under review.

11. STATUTORY AUDITORS:

Pursuant to letter no./ CA.V/COY/ASSAM,AMSCL(1)/617 dated 18/09/2023 the Comptroller and Auditor General of India has appointed M/s N.K. Choudhary & Associates, Chartered Accountants, Guwahati as the Statutory Auditor for the financial year 2023-2024.

12. AUDITORS' REPORT:

The Statutory Auditor has issued an unqualified audit opinion on the financial statements of the Corporation. The observations made therein are self-explanatory and, therefore, do not call for any further explanation by the Board.

However the previous Statutory Auditors have reported a qualification regarding the Government grant of ₹8.54 crore, which has been incorrectly classified as equity in the financial statements. As the grant is required to be classified under Capital Reserve in accordance with AS-12, Equity Capital is overstated and Capital Reserve is understated by the corresponding amount. The matter remains pending for resolution by the management.

13. BOARD EXPLANATION:

AUDITORS OBSERVATION	BOARD EXPLANATION
(a) the ₹8.54 crore grant classified as equity instead of Capital Reserve under AS-12, with no PAS-3 filed;	The remedial plan and the reference made to the Health & FW Department.
(b) the audit trail (Rule 11(g)) remark — the Tally audit trail feature was not enabled throughout the year. Neither report mentions the audit trail at all.	The operational reasons and confirmation that the feature will be enabled.

14. COMMENTS OF COMPTROLLER AND AUDITOR GENERAL OF INDIA:

The Comptroller and Auditor General of India (CA&G) have conducted a supplementary audit of the financial statements of the corporation for the year ended 31 march 2024 under section 143(6)(a) of the Companies act 2013 and issued its comments vide its letter No. AMG-II/V-I/PSU-AMSCL/3-6/2024-25/194 dated 19th August 2026.

15. DETAILS IN RESPECT OF FRAUDS REPORTED BY AUDITORS UNDER SECTION 143(12) OTHER THAN THOSE REPORTABLE TO THE CENTRAL GOVERNMENT:

During the year under review, the Statutory Auditor in their report have not reported any instances of frauds committed in the Company by its Officers or Employees under section 143(12) of the Companies Act, 2013.

16. THE WEB ADDRESS, IF ANY, WHERE ANNUAL RETURN REFERRED TO IN SUB-SECTION (3) OF SECTION 92 HAS BEEN PLACED:

The Company does not maintain any website as on the date of this Report.

17. PARTICULARS OF EMPLOYEES:

There are no such employees whose statement of particulars is required to be given pursuant to the Companies (Appointment and Remuneration of Managerial Personnel) Rules 2014.

18. SAFETY:

Although there is no separate committee for looking after the safety and security of the Corporation, but the management of the Corporation has been taking proper steps in respect of matter of quality and safety of the employees from time to time. The Corporation has framed proper systems for the safety and hygiene of the employees of the Corporation.

19. HUMAN RESOURCES:

The Corporation treats its "human resources" as one of its most important assets. The Corporation continuously invests in attraction, retention, and development of talent on an ongoing basis. A number of programs that provide focused people attention are currently underway. The Corporation thrust is on the promotion of talent internally through job rotation and job enlargement.

20. RISK MANAGEMENT POLICY:

The Corporation has appropriate risk management systems in place for identification and assessment of risks, measures to mitigate them, and mechanisms for their proper and timely monitoring and reporting. The Corporation has introduced several measures to control the risks such as efficient management at all levels and the internal audit methodologies and processes.

21. ADEQUACY OF INTERNAL FINANCIAL CONTROLS WITH REFERENCE TO FINANCIAL STATEMENTS:

The directors state that proper design, implementation and maintenance of adequate internal financial controls is ensured by the Corporation for the orderly and efficient conduct of its business, including adherence to Corporation's policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Act.

22. DEPOSITS:

The Corporation has not invited/accepted any deposits including any unsecured loans falling within the purview of Section 73 read with Companies (Acceptance of Deposits) Rules, 2014, during the year under review. Consequently, the provisions relating to disclosures of non-compliant deposits are not applicable to the Company.

23. A STATEMENT ON DECLARATION GIVEN BY INDEPENDENT DIRECTORS UNDER SUB-SECTION (6) OF SECTION 149 AND A STATEMENT REGARDING OPINION OF THE BOARD WITH REGARD TO INTEGRITY, EXPERTISE AND EXPERIENCE (INCLUDING THE PROFICIENCY) OF THE INDEPENDENT DIRECTORS APPOINTED DURING THE YEAR.

As per the provision of Sub-rule (2) of Rule 4 of Companies (Appointment and Qualification of Directors) Rules, 2014, the criteria relating to the appointment of independent directors are not applicable to the Corporation for the period under review.

Accordingly, the requirement to comment on the integrity, expertise, experience, and proficiency of independent directors and the requirement to disclose declaration under Sub section (6) of Section 149 of the Companies Act, 2013 by the independent director is not required for the Corporation for the reporting period.

24. STATUTORY DISCLOSURE:

None of the Directors of the Corporation is disqualified under the provisions of Section 164(1) of the Companies Act, 2013.

25. THE DETAILS ABOUT THE POLICY DEVELOPED AND IMPLEMENTED BY THE CORPORATION ON CORPORATE SOCIAL RESPONSIBILITY INITIATIVES TAKEN DURING THE YEAR:

The Corporation is not mandatorily required to spend a part of its income as Corporate Social Responsibility Expenditure required under the provisions of section 135 of the Companies Act, 2013.

26. DISCLOSURES UNDER SEXUAL HARASSMENT OF WOMEN AT WORKPLACE (PREVENTION, PROHIBITION & REDRESSAL) ACT, 2013:

The Corporation has an Internal Committee for resolving the complaints related to Sexual Harassment at Workplace. The Corporation provides a safe and congenial working environment to its female employees. There was no any such complaint in the hospital regarding the same. Further details are as follow:

Sl. No.	Particulars	Remarks
a.	Number of complaints of Sexual Harassment received in the Year	Nil
b.	Number of Complaints disposed off during the year	Nil
c.	Number of cases pending for more than ninety days	Nil

27. MATERNITY BENEFIT:

The Company affirms that it has duly complied with all provisions of the Maternity Benefit Act, 1961, and has extended all statutory benefits to eligible women employees during the year.

28. CONSERVATION OF ENERGY, TECHNOLOGY ABSORPTION AND FOREIGN EXCHANGE EARNINGS AND OUTGO:

A. Conservation of energy:

(i) the steps taken or impact on conservation of energy;	Not Applicable
(ii) the steps taken by the company for utilising alternate sources of energy;	Not Applicable
(iii) the capital investment on energy conservation equipments;	Not Applicable

B. Technology absorption:

(i) the efforts made towards technology absorption;	Not Applicable
(ii) the benefits derived like product improvement, cost reduction, product development or import substitution;	Not Applicable
(iii) in case of imported technology (imported during the last three years reckoned from the beginning of the financial year)-	Not Applicable
(a) the details of technology imported;	Not Applicable
(b) the year of import;	Not Applicable
(c) whether the technology been fully absorbed;	Not Applicable
(d) if not fully absorbed, areas where absorption has not taken place, and the reasons thereof; and	Not Applicable
(iv) the expenditure incurred on Research and Development.	Not Applicable

C. Foreign exchange earnings and Outgo:

There were no foreign exchange earnings and outgo during the year under review.

The particulars as required under section 134(3)(m) of the Companies Act, 2013 read with Rule 8(3) of the Companies (Accounts) Rules, 2014 in respect of conservation of energy, technology absorption is not applicable in view of the nature of business of the Corporation. There was no foreign exchange inflow or outgo during the year under review.

29. MAINTENANCE OF COST RECORDS:

The provisions of Section 148 of the Companies Act, 2013 and Companies (Cost records and Audit) Rules, 2014 (as amended from time to time) is not applicable on the Corporation.

30. DETAILS OF APPLICATION MADE OR ANY PROCEEDING PENDING UNDER THE INSOLVENCY AND BANKRUPTCY CODE, 2016:

During the financial year under review, no application has been made and no proceeding is pending against the Corporation under the Insolvency and Bankruptcy Code, 2016.

31. DETAILS OF DIFFERENCE BETWEEN VALUATION AMOUNT ON ONE TIME SETTLEMENT AND THE VALUATION DONE WHILE TAKING LOAN FROM THE BANKS OR FINANCIAL INSTITUTIONS:

During the year under review, there has been no one time settlement of Loan taken from banks and Financial Institutions.

32. PARTICULARS OF LOANS, GUARANTEES OR INVESTMENTS UNDER SECTION 186:

There were no loans, guarantees or investments made by the Corporation under Section 186 of the Companies Act, 2013 during the year under review.

33. PARTICULARS OF CONTRACTS OR ARRANGEMENTS WITH RELATED PARTIES:

The Corporation has not entered into any transactions and/or contracts covered under sub-section (1) of section 188 of the Companies Act, 2013 during the reporting financial year.

34. SUBSIDIARIES, JOINT VENTURES AND ASSOCIATE COMPANIES:

The Corporation does not have a subsidiary within the meaning of section 2(87) of the Companies Act, 2013 (Act). Also there are no associate companies within the meaning of section 2(6) of the Act.

35. DETAILS OF SIGNIFICANT AND MATERIAL ORDERS PASSED BY THE REGULATORS OR COURTS OR TRIBUNALS IMPACTING THE GOING CONCERN STATUS AND CORPORATION'S OPERATIONS IN FUTURE:

There are no significant material orders passed by the Regulators/Courts which would impact the going concern status of the Corporation and its future operations.

36. CHANGE IN THE NATURE OF BUSINESS:

There was no change in the nature of the business of the Corporation during the year under review.

37. MATERIAL CHANGES AND COMMITMENTS, IF ANY, AFFECTING THE FINANCIAL POSITION OF THE CORPORATION WHICH HAVE OCCURRED BETWEEN THE END OF THE FINANCIAL YEAR OF THE CORPORATION TO WHICH THE FINANCIAL STATEMENTS RELATE AND THE DATE OF THE REPORT:

No material change has occurred between the end of the financial year of the Corporation to which the financial statements relate and the date of the report.

38. DIRECTORS' RESPONSIBILITY STATEMENT:

Pursuant to the requirement clause (c) of sub-section (3) of Section 134 of the Companies Act, 2013, your Directors confirm that:

- i. in the preparation of the annual accounts, the applicable accounting standards had been followed along with proper explanation relating to material departures;


- ii. the directors had selected such accounting policies and applied them consistently and made judgments and estimates that are reasonable and prudent so as to give a true and fair view of the state of affairs of the Corporation at the end of the financial year and of the profit and loss of the Corporation for that period;
- iii. the directors had taken proper and sufficient care for the maintenance of adequate accounting records in accordance with the provisions of this Act for safeguarding the assets of the Corporation and for preventing and detecting fraud and other irregularities;
- iv. the directors had prepared the annual accounts on a going concern basis; and
- v. the directors had devised proper systems to ensure compliance with the provisions of all applicable laws and that such systems were adequate and operating effectively.

39. ACKNOWLEDGEMENTS:

The Directors express their sincere appreciation for the assistance and co-operation received from State Government, various departments of the State and Central Government and authorities, bankers and all the business constituents. The Directors also wish to place on record their deep sense of appreciation for the committed services of executives and staff of the Corporation in achieving the improved services during the year under review and confident that officers and staff will continue to strive hard to improve the performance of the Corporation in the years to come.

For and on behalf of the Board of Directors of
Assam Medical Services Corporation Limited


Dr Lakshmanan S., IAS
Managing Director
(DIN: 09009335)


Dr. Manoj Kumar Choudhury
Nominee Director
(DIN: 11564996)

Date: 26.08.2026
Place: Guwahati

1596

3596/MD-AMSCL

21/08/26

SPEED POST

महालेखाकार (लेखा-परीखा), असम का कार्यालय
मैदामगांव, बेलतला, गुवाहाटी-781029



OFFICE OF THE ACCOUNTANT
GENERAL (AUDIT), ASSAM
Maidamgaon, Beltola, Guwahati – 781029

No. AMG-II/V-I/PSU-AMSCL/3-6/2024-25/194

Date: 19.08.2026

To,

19 AUG 2026

The Managing Director,
Assam Medical Service Corporation Ltd.,
Central Drug Ware-house Campus, Patharquerry,
Narengi, Guwahati-781026.

CFO

AO

Sub: Comments of the Comptroller & Auditor General of India under Section 143(6)(b) of the Companies Act 2013 on the Financial Statements of the Assam Medical Services Corporation Ltd. for the year ended 31st March 2024.

Sir,

I am directed to forward herewith the comments of the Comptroller & Auditor General of India under Section 143(6)(b) of the Companies Act 2013 on the Financial Statements of Assam Medical Services Corporation Ltd. for the year 2023-24 for placing them before the Annual General Meeting of the Company.

The date of adoption of the accounts in the Annual General Meeting of the Company may please be intimated.

Five copies of the printed Annual Report of the Company, when ready, may please be sent to this office.

Receipt of this letter with its enclosures may please be acknowledged.

Enclo: As stated.

Yours faithfully,


Deputy Accountant General/AMG-III

To,

The Managing Director,

Assam Medical Services Corporation Limited,

Narengi, Guwahati – 781026.

Sub: Management letter highlighting procedural deficiencies in accounting records and internal control system.

Sir,

We had conducted the supplementary audit on the Accounts of the Company for the year 2023-24 and issued draft comments on 19.8/24. During our audit the following deficiencies were noticed in the accounting structure and accounting reports which we consider to be of material weakness in accordance to the generally accepted accounting principles.

- (i) The Company incurred an expenditure of ₹4.18 lakh in 2022-23 for the development of its website and booked it as a revenue expenditure. However, as the website is an intangible asset, it should have been treated as capital expenditure in the asset side of the Balance Sheet. Charging of this as revenue expenditure resulted in understatement of fixed assets by ₹4.18 lakh with corresponding understatement of Reserves & Surplus by the same amount.
- (ii) The Company issued work order in February 2024 for capital works of its office building at ₹1.57 crore. It paid the first running bill of ₹20.22 lakh on 24 March 2024. However, as the entire work is yet to be completed and commissioned the expenditure so incurred in this regard must be treated as capital works in progress. Wrong classification of the capital expenditure as well as charging of depreciation before commissioning of the asset resulted in understatement of profit by ₹0.34 lakh with corresponding overstatement of fixed assets by ₹19.88 lakh and understatement of Capital Works in Progress by ₹20.22 lakh.
- (iii) In the Notes to Accounts No. 2, the Company failed to disclose that apart from fees of ₹25,000 the auditor was paid ₹10,000 as reimbursement of expenses and GST of 18 *per cent* on the said amount.

The management may kindly carry out remedial/corrective action.

Yours faithfully



Deputy Accountant General

**COMMENTS OF THE COMPTROLLER AND AUDITOR GENERAL OF INDIA
UNDER SECTION 143(6)(b) OF THE COMPANIES ACT, 2013 ON THE ACCOUNTS
OF ASSAM MEDICAL SERVICES CORPORATION LIMITED FOR THE YEAR
ENDED 31st MARCH 2024.**

The preparation of Financial Statements of **ASSAM MEDICAL SERVICES CORPORATION LIMITED**, for the year ended **31 March, 2024**, in accordance with the financial reporting framework prescribed under the Companies Act, 2013 (Act) is the responsibility of the Management of the Company. The Statutory Auditors appointed by the Comptroller and Auditor General of India under Section 139 (5) of the Act are responsible for expressing opinion on the Financial Statements under Section 143 of the Act based on independent audit in accordance with the standards on auditing, prescribed under Section 143 (10) of the Act. This is stated to have been done by them vide their Audit Report dated **31 August 2024**.

I, on the behalf of the Comptroller and Auditor General of India, have conducted a supplementary audit under Section 143(6)(a) of the Act, on the Financial Statements of **ASSAM MEDICAL SERVICES CORPORATION LIMITED** for the year ended **31 March, 2024**. This supplementary audit has been carried out independently without access to the working papers of the Statutory Auditors and is limited primarily to inquiries of the Statutory Auditors and Company personnel and a selective examination of some of the accounting records. Based on supplementary audit, I would like to highlight the following significant matters under Section 143(6)(b) of the Act which have come to my attention and which, in my view, are necessary for enabling a better understanding of the Financial Statements and the related Audit Report: _ _

A. Comments on Statutory Auditor's Report

- (i) The Statutory Auditor failed to disclose the fact that the Statutory Audit Report for the previous year (F.Y. 2022-23) was yet to be adopted in the Annual General Meeting of the Company till the signing of the current Statutory Audit Report (F.Y. 2023-24) by the Statutory Auditor.
- (ii) The Statutory Auditor in Clause xvii of 'Annexure A to the Independent Auditor's Report' has commented that the Company had not incurred any cash losses during the current year financial year (F.Y.2023-24) and the year (F.Y. 2022-23) immediately preceding the current year. However, as observed from the annual accounts for the year 2022-23, there were cash losses of ₹189.18 lakh during that year. Hence, the comment given by the Statutory Auditors in their report is deficient to that extent.

**For and on behalf of the Comptroller and
Auditor General of India**



Accountant General (Audit) Assam

Date : 17-08-26 .

Place : Guwahati



Independent Auditors' Report

To the Members of
Assam Medical Services Corporation Limited

Report on the Financial Statements

We have audited the accompanying financial statements of **Assam Medical Corporation Services Limited** ('the Company'), which comprise the Balance Sheet as at 31 March 2024, the Statement of Profit and Loss and the Cash Flow Statement for the year ended, and a summary of the significant accounting policies and other explanatory information.

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid financial statements give the information required by the **Companies Act, 2013** ('Act') in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India, of the state of affairs of the Company as at March 31, 2024, its profit (or Loss)* and cash flows for the year ended on that date.

Basis for Opinion

We conducted our audit in accordance with the standards on auditing specified under section 143 (10) of the Companies Act, 2013. Our responsibilities under those Standards are further described in the auditor's responsibilities for the audit of the financial statements section of our report. We are independent of the Company in accordance with the code of ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act and the rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the code of ethics.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

However, the previous statutory auditor had reported a qualified opinion based on the below mentioned facts, which as per our discussion with the management is still pending to resolve.

- The Government grant received has wrongly been shown as equities in the Financial Statement of the Corporation which has been detailed as below:

Opening Balance Rs. 8,54,00,000

Addition during the year NIL

No Form PAS-3 (Return of allotment) is filed with the Registrar of Companies till date in regards to the above mentioned equity shown in the financial statements and so no allotment of these equity shares made till date.

Further as per AS-12, the above grant-in-aid is to be shown under capital reserve in the balance sheet under capital approach in absence of any information provided by the management in regard to the nature and purpose of government grant received. To that extent Equity capital is overstated and capital reserve is understated.

Key Audit Matters

Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the Financial Statements of the current period. These matters were addressed in the context of our audit of the Financial Statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters. We have determined the matters described below to be the key audit matters to be communicated in our report.



**Other Information – Board of Directors' Report**

The Company's Board of Directors is responsible for the preparation and presentation of its report (herein after called as "Board Report") which comprises various information required under section 134(3) of the Companies Act 2013 but does not include the financial statements and our auditor's report thereon.

Our opinion on the financial statements does not cover the Board Report and we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the Board Report and in doing so, consider whether the Board Report is materially inconsistent with the financial statements or our knowledge obtained during the course of our audit or otherwise appears to be materially misstated.

If, based on the work we have performed, we conclude that there is a material misstatement in this Board Report, we are required to report that fact. We have nothing to report in this regard.

Management's Responsibility for the Financial Statements

The Company's Board of Directors is responsible for the matters stated in Section 134(5) of the Companies Act, 2013, with respect to the preparation of these standalone financial statements that give a true and fair view of the financial position, financial performance and cash flows of the Company in accordance with the accounting principles generally accepted in India, including the Accounting Standards specified under Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Director's are also responsible for overseeing the Company's financial reporting process.

Auditors' Responsibility

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.





- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Companies Act, 2013, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls system in place and the operating effectiveness of such controls
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the Financial Statements of the current period and are therefore the key audit matters. We describe these matters in our auditor's report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication

Report on Other Legal and Regulatory Requirements

1. As required by the Companies (Auditor's Report) Order, 2020 ("the Order") issued by the Central Government of India in terms of sub-section (11) of section 143 of the Act, we give in the **Annexure "A"**, a statement on the matters specified in paragraphs 3 and 4 of the said Order.
2. As required by section 143(3) of the Act, we report that:
 - a. We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purpose of our audit.
 - b. In our opinion proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books.
 - c. The Balance Sheet, the Statement of Profit and Loss, and the Cash Flow Statement dealt with by this Report are in agreement with books of account





- d. in our opinion, the aforesaid standalone financial statements comply with the Accounting Standards specified under Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014.
- e. On the basis of the written representations received from the directors as on 31st March, 2024 taken on record by the Board of Directors, none of the directors is disqualified as on 31st March, 2024 from being appointed as a director in terms of Section 164(2) of the Act.
- f. With respect to the adequacy of the internal financial controls over financial reporting of the Company and the operating effectiveness of such controls, refers to our separate Report in "Annexure B".
- g. With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, in our opinion and to the best of our information and according to the explanations given to us:
- The Company does not have any pending litigations which would impact its financial position.
 - The Company did not have any long-term contracts including derivative contracts for which there were any material foreseeable losses.
 - There were no amounts which were required to be transferred to the Investor Education and Protection Fund by the Company.
 - No dividend had been declared or paid during the year by the Company.
 - The company has maintained its accounts in Tally software which has the feature of recording the Audit trail. However, the said feature has not been upgrade and enable throughout the year and hence, has not operated for the whole year. Since the Audit trail feature has not been enable throughout the year, the question of tampering with the said feature doesn't arise. It has been informed to us by the Management that they are aware of the regulatory requirement of using Audit trail compliance software which they could not enable during the year due to some operational and practical reasons. However, as a part of its commitments to fully comply with the regulatory requirements, the said feature shall be enabled next year.
3. As required by section 143(5) of the Act, direction and sub direction issued by the Comptroller and Auditor General of India, we give our comments thereon in the "Annexure-C".

For **N. K. Choudhary & Associates**

Chartered Accountants

FRN: 319216E

CA Niranjan Kumar Choudhary

Partner

M. No. 054570



Guwahati, Assam

August 31, 2024

UDIN: 24054570BKHSWT4035


Annexure "A" to the Independent Auditor's Report of even date to the members of Assam Medical Services Corporation Limited, on the financial statements for the year ended 31st March 2024

i.

(a) The company has maintained proper records showing full particulars including quantitative details and situation of Property, Plant and Equipment.

(b) Property, Plant and Equipment have been physically verified by the management at reasonable intervals during the year and no material discrepancies were identified on such verification.

(c) As informed to us by the management and on the basis of our examination of record, the following property accounts for in the books of Accounts of the Company but not held in its name:

Description of the property	Gross Carrying Amount (in Rs.)	Held in the name of	Whether title deed holder is a promoter, director or relative of promoter/director or employee of promoter/director	Period held	Reason for not being in the name of the Company
Building (Part of Ground Floor and Second Floor) and Central Drugs Warehouse Campus, Patharquarry, Narengi, Guwahati-781026	2,81,70,829/-	Health and Family Welfare Department, government of Assam	Not Applicable	NA	It is a Government property under the Health and Family Welfare Department and handed over to AMSCL for use of office and building

(d) According to the information and explanations given to us, the Company has not revalued its property, plant and Equipment (including Right of Use assets) and its intangible assets. Accordingly, the requirements under paragraph 3(i)(d) of the Order are not applicable to the Company.

(e) According to the information and explanations given to us, no proceeding has been initiated or pending against the Company for holding benami property under the Benami Transactions (Prohibition) Act, 1988 and rules made thereunder. Accordingly, the provisions stated in paragraph 3(i) (e) of the Order are not applicable to the Company.

ii. The company does not have any inventory and no working capital limits in excess of five crore rupees (at any point of time during the year), in aggregate, from banks, or financial institutions on the basis of security of current assets. Accordingly, the provisions of clause 3(ii) of the Order are not applicable.

iii. According to the information explanation provided to us, the Company has not made any investments in, provided any guarantee or security or granted any loans or advances in the nature of loans, secured or unsecured, to companies, firms, Limited Liability Partnerships or any other parties. Hence, the requirements under paragraph 3(iii) of the Order are not applicable to the Company.

iv. In our opinion and according to the information and explanations given to us, the Company has not either directly or indirectly, granted any loan to any of its directors or to any other person in whom the director is interested, in accordance with the provisions of section 185 of the Act and the Company has not made investments through more than two layers of investment companies in accordance with the





provisions of section 186 of the Act. Accordingly, provisions stated in paragraph 3(iv) of the Order are not applicable to the Company.

v. In our opinion and according to the information and explanations given to us, the Company has complied with the provisions of sections 73, 74, 75 and 76 of the Act, the rules framed thereunder and the Circulars, notifications issued from time to time with regard to the deposits accepted. No order has been passed by the Company Law Board or National Company Law Tribunal or Reserve Bank of India or any Court or any other Tribunal in this respect.

vi. The provisions of sub-section (1) of section 148 of the Act are not applicable to the Company as the Central Government of India has not specified the maintenance of cost records for any of the products of the Company. Accordingly, the provisions stated in paragraph 3 (vi) of the Order are not applicable to the Company.

vii.

(a) According to the information and explanations given to us and the records of the Company examined by us, in our opinion, undisputed statutory dues including goods and service tax, provident fund, employees' state insurance, income-tax, sales-tax, service tax, duty of customs, duty of excise, value added tax, cess have been regularly deposited by the company with appropriate authorities in all cases during the year.

(b) According to the information and explanation given to us and the records of the Company examined by us, there are no dues of income tax, goods and service tax, customs duty, cess and any other statutory dues which have not been deposited on account of any dispute.

viii. According to the information and explanations given to us, there are no transactions which are not accounted in the books of account which have been surrendered or disclosed as income during the year in Tax Assessment of the Company. Also, there are no previously unrecorded income which has been now recorded in the books of account. Hence, the provision stated in paragraph 3(viii) of the Order is not applicable to the Company.

ix.

(a) In our opinion and according to the information and explanations given to us, the Company has not defaulted in repayment of loans or borrowings or in payment of interest thereon to any lender.

(b) According to the information and explanations given to us and on the basis of our audit procedures, we report that the company has not been declared willful defaulter by any bank or financial institution or government or any government authority.

(c) In our opinion and according to the information explanation provided to us, no money was raised by way of term loans. Accordingly, the provision stated in paragraph 3(ix)(c) of the Order is not applicable to the Company.

(d) In our opinion, according to the information explanation provided to us, there are no funds raised on short term basis. Accordingly, the provision stated in paragraph 3(ix)(d) of the Order is not applicable to the Company.

(e) According to the information explanation given to us and on an overall examination of the standalone financial statements of the Company, we report that the company has not taken any funds from an any entity or person on account of or to meet the obligations of its subsidiaries, associates or joint ventures.

(f) According to the information and explanations given to us and procedures performed by us, we report that the Company has not raised loans during the year on the pledge of securities held in its securities, joint ventures or associate companies.





x.

(a) The Company did not raise any money by way of initial public offer or further public offer (including debt instruments) during the year. Accordingly, the provisions stated in paragraph 3 (x)(a) of the Order are not applicable to the Company.

(b) According to the information and explanations given to us and based on our examination of the records of the Company, the Company has not made any preferential allotment or private placement of shares or fully, partly or optionally convertible debentures during the year. Accordingly, the provisions stated in paragraph 3 (x)(b) of the Order are not applicable to the Company.

xi.

(a) During the course of our audit, examination of the books and records of the Company, carried out in accordance with the generally accepted auditing practices in India, and according to the information and explanations given to us, we have neither come across any instance of fraud by the Company nor on the Company.

(b) We have not come across of any instance of fraud by the Company or on the Company during the course of audit of the standalone¹ financial statement for the year ended March 31, 2024, accordingly the provisions stated in paragraph (xi)(b) of the Order is not applicable to the Company.

(c) As represented to us by the management, there are no whistle-blower complaints received by the Company during the year. Accordingly, the provisions stated in paragraph (xi)(c) of the Order is not applicable to company.

xii. In our opinion and according to the information and explanations given to us, the Company is not a Nidhi Company. Accordingly, the provisions stated in paragraph 3(xii) (a) to (c) of the Order are not applicable to the Company.

xiii. According to the information and explanations given to us and based on our examination of the records of the Company, transactions with the related parties are in compliance with sections 177 and 188 of the Act where applicable and details of such transactions have been disclosed in the standalone financial statements as required by the applicable accounting standards.

xiv. In our opinion and based on our examination, the Company does not require to comply with provision of section 138 of the Act. Hence, the provisions stated in paragraph 3(xiv) (a) to (b) of the Order are not applicable to the Company.

xv. According to the information and explanations given to us, in our opinion during the year the Company has not entered into non-cash transactions with directors or persons connected with its directors and hence, provisions of section 192 of the Act are not applicable to company. Accordingly, the provisions stated in paragraph 3(xv) of the Order are not applicable to the Company.

xvi. In our opinion, the Company is not required to be registered under section 45 IA of the Reserve Bank of India Act, 1934 and accordingly, the provisions stated in paragraph clause 3 (xvi)(a) of the Order are not applicable to the Company.

xvii. Based on the overall review of standalone¹ financial statements, the Company has not incurred cash losses in the current financial year and in the immediately preceding financial year. Hence, the provisions stated in paragraph clause 3 (xvii) of the Order are not applicable to the Company.





xviii. There has been no resignation of the statutory auditors during the year. Hence, the provisions stated in paragraph clause 3 (xviii) of the Order are not applicable to the Company.

xix. According to the information and explanations given to us and based on our examination of financial ratios, ageing and expected date of realisation of financial assets and payment of liabilities, other information accompanying the standalone¹ financial statements, our knowledge of the Board of Directors and management plans, we are of the opinion that no material uncertainty exists as on the date of audit report and the Company is capable of meeting its liabilities existing at the date of balance sheet as and when they fall due within a period of one year from the balance sheet date.

xx.

(a) According to the information and explanations given to us, the provisions of section 135 of the Act are not applicable to the Company. Hence, the provisions of paragraph (xx)(a) to (b) of the Order are not applicable to the Company.

xxi. The reporting under clause 3(xxi) of the Order is not applicable in respect of audit of standalone financial statements. Accordingly, no comment in respect of the said clause has been included in the report.

For N. K. Choudhary & Associates

Chartered Accountants

FRN: 319216E

CA Niranjan Kumar Choudhary

Partner

M. No. 054570



Guwahati, Assam

August 31, 2024

UDIN:

**Annexure "B" to the Standalone Independent Auditor's Report****Report on the Internal Financial Controls under Clause (i) of Sub-section 3 of Section 143 of the Companies Act, 2013 ("the Act")**

We have audited the internal financial controls over financial reporting of **Assam Medical Services Corporation Limited** ("the Company") as of March 31, 2024 in conjunction with our audit of the standalone financial statements of the Company for the year ended on that date.

Management's Responsibility for Internal Financial Controls

The Company's management is responsible for establishing and maintaining internal financial controls based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls over Financial Reporting issued by the Institute of Chartered Accountants of India. These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to company's policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Companies Act, 2013.

Auditors' Responsibility

Our responsibility is to express an opinion on the Company's internal financial controls over financial reporting based on our audit. We conducted our audit in accordance with the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting (the "Guidance Note") and the Standards on Auditing, issued by ICAI and deemed to be prescribed under section 143(10) of the Companies Act, 2013, to the extent applicable to an audit of internal financial controls, both applicable to an audit of Internal Financial Controls and, both issued by the Institute of Chartered Accountants of India. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls over financial reporting was established and maintained and if such controls operated effectively in all material respects.





Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls system over financial reporting and their operating effectiveness. Our audit of internal financial controls over financial reporting included obtaining an understanding of internal financial controls over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the Company's internal financial controls system over financial reporting.

Meaning of Internal Financial Controls over Financial Reporting

A company's internal financial control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal financial control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.

Inherent Limitations of Internal Financial Controls over Financial Reporting

Because of the inherent limitations of internal financial controls over financial reporting, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls over financial reporting to future periods are subject to the risk that the internal financial control over financial reporting may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.





Opinion

In our opinion, the Company has, in all material respects, an adequate internal financial controls system over financial reporting and such internal financial controls over financial reporting were operating effectively as at March 31, 2024, based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India.

For N. K. Choudhary & Associates

Chartered Accountants

FRN: 319216E

CA Niranjana Kumar Choudhary

Partner

M. No. 054570



Guwahati, Assam

August 31, 2024

**Annexure "C" to Independent Auditors Report**

(Referred to in paragraph 3 under "Report on other Legal and Regulatory Requirements" of our report of even date to the members of **Assam Medical Services Corporation Limited** on the standalone financial statements for the year ended 31st March, 2024

Sl. No.	Directions	Comments
1	Whether the company has system in place to process all the accounting transactions through IT system? If yes, the implications of processing of accounting transactions outside IT system on the integrity of the accounts along with the financial implications, if any, may be stated.	The company has maintained its accounts in Tally software which has the feature of recording the Audit trail. However, the said feature has not been upgraded or enabled throughout the year.
2	Whether there is any restructuring of an existing loan or cases of waiver/write off of debts loans/interest etc. made by a lender to the company due to the company's inability to repay the loan? If yes, the financial impact may be stated.	No case of restructuring of an existing loan, waiver /write off of debts/loans/interest etc. was observed.
3	Whether funds received/receivable for specific schemes from central/ state agencies were properly accounted for/ utilized as per its term and conditions? List the cases of deviation.	Properly accounted/ utilized for except as mentioned in the "Basis of Opinion" paragraph.

For **N. K. Choudhary & Associates**

Chartered Accountants

FRN: 319216E

CA Niranjan Kumar Choudhary

Partner

M. No. 054570



Guwahati, Assam

August 31, 2024

Statement of Profit and loss for the year ended 31st March 2024

₹ in lakhs

Particulars	Note No.	31st March 2024	31st March 2023
Revenue			
Revenue from operations	11	1,452.96	
Less: Excise duty			
Net Sales		1,452.96	
Other income	12	71.31	8.71
Total Income		1,524.27	8.71
Expenses			
Cost of material Consumed			
Purchase of stock-in-trade			
Changes in inventories			
Employee benefit expenses	13	266.93	60.35
Finance costs			
Depreciation and amortization expenses	14	22.70	6.81
Other expenses	15	235.46	129.86
Total expenses		525.09	197.01
Profit before exceptional, extraordinary and prior period items and tax		999.18	(188.30)
Exceptional items			
Profit before extraordinary and prior period items and tax		999.18	(188.30)
Extraordinary items			
Prior period item			
Profit before tax		999.18	(188.30)
Tax expenses			
Current tax	16	214.00	
Deferred tax		(0.17)	7.92
Excess/short provision relating earlier year tax			
Profit(Loss) for the period		785.35	(196.22)
Earning per share-in ₹			
Basic	17		
Before extraordinary Items		91.96	(22.98)
After extraordinary Adjustment		91.96	(22.98)
Diluted			
Before extraordinary Items			
After extraordinary Adjustment			

SIGNIFICANT ACCOUNTING POLICIES & NOTES TO THE ACCOUNTS

18

The accompanying notes are an integral part of the financial statements.

As per our report of even date

For N. K. CHOUDHARY AND ASSOCIATES

Chartered Accountants


(FRN: 0319216E)

NIRANJAN KUMAR CHOUDHARY
PARTNER

Membership No.: 054570

Place: GUWAHATI

Date: 31/08/2024



RAJAT DEKA
CFO
DIN: AGUPD3799F
Address: Guwahati, Assam

For and on behalf of the Board of Directors

DR. ANUP KUMAR BARMAN
Director
DIN: 07523955
Address: Guwahati, Assam

DR. ROBIN KUMAR
Managing Director
DIN: 09442400
Address: Guwahati, Assam

Central Drug Warehouse Campus, Patherquery, Narengi
Guwahati, Kamrup Metro-781026
CIN : U85320AS2016SGC017461

Balance Sheet as at 31st March 2024

₹ in lakhs

Particulars	Note No.	As at 31st March 2024	As at 31st March 2023
EQUITY AND LIABILITIES			
Shareholder's funds			
Share capital	1	854.00	854.00
Reserves and surplus	2	548.24	(237.11)
Money received against share warrants			
		1,402.24	616.89
Share application money pending allotment			
Non-current liabilities			
Long-term borrowings			
Deferred tax liabilities (Net)	3	5.85	6.03
Other long term liabilities			
Long-term provisions	4		
		5.85	6.03
Current liabilities			
Short-term borrowings			
Trade payables	5		
(A) Micro enterprises and small enterprises			
(B) Others		1,997.14	63.22
Other current liabilities	6	24,293.74	29,893.56
Short-term provisions	4	214.00	
		26,504.88	29,956.78
TOTAL		27,912.97	30,579.70
ASSETS			
Non-current assets			
Property, Plant and Equipment and Intangible assets	7		
Property, Plant and Equipment		358.32	245.03
Intangible assets			
Capital work-in-Progress			
Intangible assets under development			
Non-current investments			
Deferred tax assets (net)	3		
Long-term loans and advances	8		
Other non-current assets			
		358.32	245.03
Current assets			
Current investments			
Inventories			
Trade receivables			
Cash and cash equivalents	9	27,320.68	30,317.46
Short-term loans and advances	8	88.11	16.29
Other current assets	10	145.86	0.92
		27,554.65	30,334.67
TOTAL		27,912.97	30,579.70

SIGNIFICANT ACCOUNTING POLICIES & NOTES TO THE ACCOUNTS

18

The accompanying notes are an integral part of the financial statements.

As per our report of even date

For N. K. CHOUDHARY AND ASSOCIATES

Chartered Accountants

(FRN: 0319216E)

NIRANJAN KUMAR CHOUDHARY

PARTNER

Membership No.: 054570

Place: GUWAHATI

Date: 31/08/2024



DR. ANUP KUMAR BARMAN
CFO

DIN: AGUPD3799F

Address: Guwahati, Assam

For and on behalf of the Board of Directors

DR. ANUP KUMAR BARMAN

Director

DIN: 07523955

Address: Guwahati, Assam

DR. ROBIN KUMAR

Managing Director

DIN: 09442400

Address: Guwahati, Assam

CASH FLOW STATEMENT FOR THE YEAR ENDED 31st March 2024

₹ in lakhs

	PARTICULARS	31st March 2024	31st March 2023
A.	Cash Flow From Operating Activities		
	Net Profit before tax and extraordinary items(as per Statement of Profit and Loss)	999.18	(188.30)
	Adjustments for non Cash/ Non trade Items:		
	Depreciation & Amortization Expenses	22.70	6.81
	Interest received	(24.88)	(7.69)
	Operating profits before Working Capital Changes	997.00	(189.18)
	Adjusted For:		
	Increase / (Decrease) in trade payables	1,933.92	58.23
	Increase / (Decrease) in other current liabilities	(5,385.82)	29,892.21
	(Increase) / Decrease in Short Term Loans & Advances	(71.82)	(16.29)
	(Increase) / Decrease in other current assets	(144.94)	1.23
	Cash generated from Operations	(2,671.65)	29,746.20
	Net Cash flow from Operating Activities(A)	(2,671.65)	29,746.20
B.	Cash Flow From Investing Activities		
	Purchase of tangible assets	(135.99)	(31.09)
	Interest Received	24.88	7.69
	Net Cash used in Investing Activities(B)	(111.12)	(23.40)
C.	Cash Flow From Financing Activities		
	Other Inflows / (Outflows) of cash	(214.00)	
	Receipt of Government Subsidy		304.00
	Net Cash used in Financing Activities(C)	(214.00)	304.00
D.	Net Increase / (Decrease) In Cash & Cash Equivalents(A+B+C)	(2,996.77)	30,026.80
E.	Cash & Cash Equivalents at Beginning of period	30,317.46	290.66
F.	Cash & Cash Equivalents at End of period	27,320.69	30,317.46
G.	Net Increase / (Decrease) In Cash & Cash Equivalents(F-E)	(2,996.77)	30,026.80
H.	Difference (F-(D+E))		

The accompanying notes are an integral part of the financial statements.

As per our report of even date

For N. K. CHOUDHARY AND ASSOCIATES

Chartered Accountants

(FRN: 0319216E)

NIRANJAN KUMAR CHOUDHARY

PARTNER

Membership No.: 054570

Place: GUWAHATI

Date: 31/08/2024



SWAJIT DEKA

CFO

DIN: AGUPD3799F

Address: Guwahati, Assam

For and on behalf of the Board of Directors

DR. ANUP KUMAR BARMAN

Director

DIN: 07523955

Address: Guwahati, Assam

DR. ROBIN KUMAR

Managing Director

DIN: 09442400

Address: Guwahati, Assam

Note:

1. The Cash Flow Statement has been prepared by Indirect Method as per AS-3 issued by ICAI.
2. Figures of previous year have been rearranged/regrouped wherever necessary
3. Figures in brackets are outflow/deductions

Notes to Financial statements for the year ended 31st March 2024

The previous year figures have been regrouped / reclassified, wherever necessary to confirm to the current year presentation.

Note No. 1 Share Capital

₹ in lakhs

Particulars	As at 31st March 2024	As at 31st March 2023
Authorised :		
1500000 (31/03/2023:1500000) Equity shares of Rs. 100.00/- par value	1,500.00	1,500.00
Issued :		
854000 (31/03/2023:854000) Equity shares of Rs. 100.00/- par value	854.00	854.00
Subscribed and paid-up :		
854000 (31/03/2023:854000) Equity shares of Rs. 100.00/- par value	854.00	854.00
Total	854.00	854.00

Reconciliation of the Shares outstanding at the beginning and at the end of the reporting period

Equity shares

₹ in lakhs

	As at 31st March 2024		As at 31st March 2023	
	No. of Shares	Amount	No. of Shares	Amount
At the beginning of the period	8,54,000	854.00	5,50,000	550.00
Issued during the Period			3,04,000	304.00
Redeemed or bought back during the period				
Outstanding at end of the period	8,54,000	854.00	8,54,000	854.00

Right, Preferences and Restriction attached to shares

Equity shares

The company has only one class of Equity having a par value Rs. 100.00 per share. Each shareholder is eligible for one vote per share held. The dividend proposed by the board of directors is subject to the approval of the shareholders in ensuing Annual General Meeting, except in case of interim dividend. In the event of liquidation, the Equity shareholders are eligible to receive the remaining assets of the company after distribution of all preferential amounts, in proportion to their shareholding.

Note No. 2 Reserves and surplus

₹ in lakhs

Particulars	As at 31st March 2024	As at 31st March 2023
Surplus		
Opening Balance	(237.11)	(40.89)
Add: Profit for the year	785.35	
Less: Loss for the year		(196.22)
Closing Balance	548.24	(237.11)
Balance carried to balance sheet	548.24	(237.11)

Note No. 3 Deferred Tax

₹ in lakhs

Particulars	As at 31st March 2024	As at 31st March 2023
Deferred tax liability		
Deferred Tax Liabilities	5.85	6.03
Gross deferred tax liability	5.85	6.03
Net deferred tax liability	5.85	6.03

Note No. 4 Provisions

₹ in lakhs

Particulars	As at 31st March 2024			As at 31st March 2023		
	Long-term	Short-term	Total	Long-term	Short-term	Total
Other provisions						
Current tax provision		214.00	214.00			
Total		214.00	214.00			



GM-CFO(F&A)
AMSCL

Note No. 5 Trade payables

₹ in lakhs

Particulars	As at 31st March 2024	As at 31st March 2023
(B) Others		
Trade Payable	1,997.14	63.22
	1,997.14	63.22
Total	1,997.14	63.22

Trade Payables Ageing Schedule

₹ in lakhs

Payment date not defined (Outstanding for following periods from due date of Transaction)

Particular	Current Year					Previous Year				
	Less than 1 Yrs	1-2 Years	2-3 Years	More than 3 Yrs	Total	Less than 1 Yrs	1-2 Years	2-3 Years	More than 3 Yrs	Total
MSME					0.00					0.00
Others	1997.14				1997.14	63.22				63.22
Disputed Dues-MSME					0.00					0.00
Disputed- Others					0.00					0.00

Note No. 6 Other current liabilities

₹ in lakhs

Particulars	As at 31st March 2024	As at 31st March 2023
Others payables		
Interest Payable	285.02	44.94
Procurement of Grant Received	23,477.42	29,403.19
Performance Security	132.22	35.04
Duties and Taxes	294.50	351.24
EMD Deposit	93.06	59.15
Tender Fees	0.02	
Framework Agreement Fees	0.03	
DDWH Payable (Transportation Charges)	10.14	
Employee & Others	1.34	
	24,293.74	29,893.56
Total	24,293.74	29,893.56



[Signature]
GM-CFO(F&A)
AMSCL

Note No. 7 Property, Plant and Equipment and Intangible assets as at 31st March 2024

₹ in lakhs

Assets	Useful Life (in Years)	Balance as at 1st April 2023	Additions during the year	Revaluation increase (decrease)	Deletion during the year	Increase (Decrease) through net exchange difference	Other Adjustment (Gross Block)	Balance as at 31st March 2024	Accumulated Depreciation/ Amortisation				Net Block	
									Balance as at 1st April 2023	Provided during the year	Deletion / adjustments during the year	Balance as at 31st March 2024	Balance as at 31st March 2024	Balance as at 31st March 2023
A Tangible assets														
Own Assets														
Office Building	60.00	212.64	69.07					281.71	3.52	3.69		7.22	274.49	209.11
Furniture & Fixture	10.00	3.57	35.61					39.18	0.36	1.46		1.82	37.36	3.21
Computer & Peripherals	3.00	30.50	19.00					49.50	2.40	14.69		17.09	32.41	28.11
Office Equipment	5.00	5.52	12.32					17.84	0.93	2.85		3.78	14.06	4.59
Total (A)		252.24	135.99					388.23	7.21	22.70		29.91	358.32	245.03
P.V Total		11.57	240.67					252.24	0.40	6.81		7.21	245.03	11.16

General Notes :

1. No depreciation if remaining useful life is negative or zero.
2. Depreciation is calculated on pro-rata basis in case assets is purchased/sold during current F.Y.
3. If above assets is used for any time during the year for double shift, the depreciation will increase by 50% for that period and in case of the triple shift the depreciation shall be calculated on the basis of 100% for that period.
4. In case of leap year, depreciation is calculated on the basis of 366 days in a year.



GM-Clifford A
AMSCl

Note No. 8 Loans and advances

₹ in lakhs

Particulars	As at 31st March 2024		As at 31st March 2023	
	Long-term	Short-term	Long-term	Short-term
Other loans and advances				
Unsecured, considered good(Head)		88.11		16.29
		88.11		16.29
Total		88.11		16.29

Note No. 9 Cash and cash equivalents

₹ in lakhs

Particulars	As at 31st March 2024	As at 31st March 2023
Balance with banks		
HDFC A/C 50100549564479 (State Budget)	16,454.09	18,326.77
HDFC AMSCL Holding A/C NO 6920		72.27
HDFC AMSCL NHM Fund (SB) 6268	7,382.60	11,156.62
HDFC ASACS Fund - 50100630969257	996.61	
HDFC AYUSH Fund - 50100630969283	657.86	
HDFC EMD A/C 50100516234601	168.38	376.76
HDFC PIP SNA A/C-50100491751610		1.49
SBI A/C NO-37862545509	1,660.80	383.55
Total	27,320.34	30,317.46
Cash in hand		
Cash in hand	0.34	
Total	0.34	
Total	27,320.68	30,317.46

Note No. 10 Other current assets

₹ in lakhs

Particulars	As at 31st March 2024	As at 31st March 2023
Other Assets		
TCS (AY 23-24)		0.92
TCS (AY 24-25)	88.55	
Income Tax (AY 24-25)	7.00	
Income Tax TDS (AY 24-25)	0.01	
NHM Receivable (EMD)	50.30	
Total	145.86	0.92

Note No. 11 Revenue from operations

₹ in lakhs

Particulars	31st March 2024	31st March 2023
Sale of services		
Income from Service Charges	1,452.96	
	1,452.96	
Net revenue from operations	1,452.96	

Note No. 12 Other Income

₹ in lakhs

Particulars	31st March 2024	31st March 2023
Interest Income		
Interest on Income Tax Refund	0.04	
Interest received on Savings Account	4.17	0.79
Interest received on Savings Account (Grant in Aid)	20.67	6.90
	24.88	7.69
Other non-operating income		
Other receipts	46.44	1.02
	46.44	1.02
Total	71.32	8.71



[Signature]
GM-CFO(F&A)
AMSCL

Note No. 13 Employee benefit expenses

₹ in lakhs

Particulars	31st March 2024	31st March 2023
Salaries and Wages		
Remuneration to Staff	266.74	60.35
	266.74	60.35
Staff welfare Expenses	0.20	
Total	266.94	60.35

Note No. 14 Depreciation and amortization expenses

₹ in lakhs

Particulars	31st March 2024	31st March 2023
Depreciation on tangible assets	22.70	6.81
Total	22.70	6.81

Note No. 15 Other expenses

₹ in lakhs

Particulars	31st March 2024	31st March 2023
Advertising expenses	120.58	59.01
Audit fees	3.15	1.55
Bank charges		
Other expenditure	85.55	48.83
Conveyance expenses	0.01	
Printing and stationery	3.84	1.49
Conveyance expenses		
Professional expenses	5.66	4.26
ROC Filing Fee	0.01	0.10
Security expenses	10.13	11.11
Telephone expenses	4.12	0.53
Travelling Expenses	2.40	3.00
Total	235.46	129.86

Note No. 16 Current tax

₹ in lakhs

Particulars	31st March 2024	31st March 2023
Current tax pertaining to current year	214.00	
Total	214.00	



[Signature]
GM-CFO(F&A)
AMSCL

Note No. 5(a)(a) Trade payables:(B) Others: Trade Payable

₹ in lakhs

Particulars	31st March 2024	31st March 2023
ABOTT INDIA LTD	0.33	
ADVANCED MEDITECH SOLUTION PVT LTD	3.36	
AGAM PHARMACEUTICAL	5.05	
AGRON REMEDIES PVT LTD	4.78	
Amar Asom(G L Publication)	0.07	
AMSTER LABS UNIT II	11.82	
ASSAM TRIBUNE PVT LTD		2.47
Audit Fees Payable	2.90	1.55
BDR PHARMACEUTICAL INTERNATIONAL PVT LTD	4.21	
BETTER POWER SERVICES PVT LTD	32.38	
BHARAT SERUM AND VACCINE LTD	30.13	
BIMAN DEBNATH & ASSOCIATES	0.12	0.12
CIPLA LTD	11.10	
CMG BIOTECH PVT LTD	0.15	
DAL THOMS SCIENTIFIC	0.24	
DHS (FW)		0.02
DR REDDY'S LAB LTD	49.63	
D.S SYSTEMS PVT LTD	18.26	
DYNAMIC TRACOM PVT LTD	0.58	
FRESENIUS KABI INDIA PVT LTD	7.58	
GRIFOLS INDIA HEALTHCARE PVT LTD	22.36	
HARDIK MEDITECH	17.14	
HEALERS LAB	0.78	
HETERO HEALTHCARE LTD	1.19	
HT MEDIA		14.84
INDIAN IMMUNOLOGICALS LIMITED	48.93	
IPCA LABORATORIES	1.33	
ITAS G PHARMA	326.97	
J.M DISTRIBUTOR	187.92	
Johnson & Johnson Pvt Ltd	159.01	
JYOTI PHARMACEUTICAL	8.19	
LEAP TECHNOLOGY	1.73	
MAINDEOR ENTERPRISE	4.26	
MARAK SUPPLY & AGENCIES	25.19	
MARTIN & BROWN BIO SCIENCES	21.56	
M.B TRADERS	64.41	41.16
MERIL DIAGNOSTICS PVT LTD	9.76	
MERIL ENDO SURGERY PVT LTD	11.13	
MICROGENE DIAGNOSTICS SYSTEM PVT LTD		
M/S AUDITIVO HEARING SERVICES PVT LTD	129.82	
M/S SYSTRONICS	73.77	
NEKIBUR ZAMAN AHMED	6.05	
NESTOR PHARMACEUTICALS LTD	0.08	
Paviour Pharmaceuticals Pvt Ltd	130.08	
P.C FORMS & STATIONARY	0.97	
PROGRESSIVE ENTERPRISES	93.25	
PROTECH TELELINKS	0.70	
RAMESH PRABHAW & CO	0.02	
RAYVOLTS POWER PRIVATE LIMITED	0.14	
REMI ELECTROTECHNIK LIMITED	118.42	
Rocky Enterprise	0.03	0.03
Rusan Pharma Ltd	0.14	
Saar Biotech Pvt Ltd	32.98	
SANOFI INDIA LTD		2.59
SERUM INSTITUTE OF INDIA	29.36	
SHIWALI DRUGS & SURGICAL	0.09	
SHRINIWAS POLYFABRICS & PACKWELL PVT LTD.	0.46	



[Signature]
GM-CFO(F&A)
AMSCL

SUBHYATRA	0.15	
SYNOKEM PHARMACEUTICALS LTD	57.03	
TRANSASIA BIO MEDICAL	223.79	
UNICURE INDIA LTD	4.12	
VASUDEV ENTERPRISE	0.02	
VINAYAK TOURS & TRAVELS	1.13	0.46
Total	1,997.14	63.22

Note No. 6(a)(a) Other current liabilities: Interest Payable

₹ in lakhs

Particulars	31st March 2024	As at 31st March 2023
ASACS SB Interest Payable	5.97	0.68
AYUSH SB Interest Payable	23.71	1.01
NHM SB Interest Payable	255.34	43.24
Total	285.02	44.94

Note No. 6(b)(b) Other current liabilities: Procurement of Grant Received

₹ in lakhs

Particulars	31st March 2024	As at 31st March 2023
National Health Mission (NHM)	22,247.95	28,988.33
Assam State Aids Control Society (ASACS)	585.38	246.39
DHS (FW)	0.51	
AYUSH	643.58	168.48
Total	23,477.42	29,403.19

Note No. 6(c)(c) Other current liabilities: Performance Security

₹ in lakhs

Particulars	31st March 2024	As at 31st March 2023
Abbott India Limited PBG	0.02	0.02
ABOTT INDIA PBG	1.61	
Adven Biotech PBG	0.01	
AKUMS DRUGS & PHARMACEUTICALS LTD PBG	0.59	0.50
ALPA LABORATORIES PBG	0.08	
AMAR PHARMACEUTICALS PBG	0.03	
AMSTER LAB PBG	0.70	
ATHENESE DX PBG	0.03	0.03
BAJAJ HEALTHCARE PBG	1.54	
BDR Pharmaceuticals International Pvt. Ltd. PBG	0.28	
Beta Drugs Limited PBG	0.93	0.93
Bharat Parenterals Limited PBG	0.06	0.06
BIOCARE ASSOCIATES PBG	1.51	
BIOCON BIOLOGICS PBG	0.71	0.71
BIO DEAL PHARMACEUTICALS PBG	1.61	
Biogenix Inc Pvt Ltd PBG	3.25	
B JAIN PHARMACEUTICALS PVT LTD PBG	0.11	
BRIYOSIS SOFT CAPS PVT LTD PBG	0.36	
Celebrity Bio Pharma PBG	0.03	
CELON LABORATORIES PBG	0.49	
Cipco Pharmaceuticals PBG	0.05	
CIPLA LTD PBG	3.01	0.25
CONCORD BIOTECH PBG	4.06	1.36
DIVINE LABORATORIES PBG	0.52	0.13
EAST AFRICAN INDIA OVERSEAS PBG	1.96	0.79
EASTERN HEALTHCARE PBG	0.03	0.03
EISAI PHARMACEUTICALS INDIA PVT LTD PBG	0.68	0.68
FERRING PHARMACEUTICAL PBG	4.22	1.13
GETWELL PHARMACEUTICALS PBG	1.19	0.47
Getwell Pharma India Pvt Ltd PBG	0.20	
Glenmark Pharmaceuticals PBG	0.02	
GLOBELA PHARMA PRIVATE LIMITED PBG	0.01	0.01
GLS PHARMA LIMITED PBG	0.13	0.09



[Signature]
GM-CFO(F&A)
AMSCL

GUFIC BIO SCIENCE PBG	0.47	
Healthium Medtech Ltd PBG	1.32	0.69
HIGGIS HEALTHCARE PBG	1.61	
HLL LIFECARE PBG	1.56	
INDIA MEDTRONIC PVT LTD PBG	5.74	1.37
Indian Immunological PBG	0.81	
INDIAN MEDICINES PHARMACEUTICAL PBG	0.07	
IPCA Laboratories Limited PBG	0.01	0.01
ITAS G PHARMA PBG	0.06	
Jackson Laboratories PBG	0.03	
J.M DISTRIBUTOR PBG	0.81	
Jodas Expoim Pvt Ltd PBG	0.99	
JYOTI PHARMACEUTICAL PBG	1.15	
KARNANI PHARMACEUTICALS P LTD PBG	0.01	
KERELA AYURVEDIC SOCIETY PBG	0.68	
KHANDELWAL LABORATORIES PVT LTD PBG	0.21	
Life Max Cancer Laboratories PBG	13.46	
Maindeor Enterprise PBG	0.04	
MASCOT HEALTH SERIES PVT LTD PBG	3.14	0.38
Medisol Lifescience Pvt Ltd PBG	0.23	
Med Source PBG	0.09	0.09
MICRON PHARMACEUTICALS PBG	0.09	
MIDAS CARE PHARMACEUTICALS PBG	0.06	0.06
Midascare Pharmaceuticals Pvt Ltd PBG	0.07	0.07
MSN LABORATORIES PBG	0.01	
M/S SUNGHILLA ENTERPRISE SECURITY DEPOSIT	1.01	
NAPROD LIFESCIENCE PBG	1.25	0.22
NEKIBUR ZAMAN SECURITY DEPOSIT 5%	1.13	
OM BIOMEDIC PVT LTD PBG	0.04	0.02
Oscar Remedies PBG	0.42	
P BHOGILAL PVT LTD PBG	3.94	
PERFORMANCE SECURITY UNRECONCILED	0.14	
PETER SURGICAL PBG	1.31	0.58
PLASMAGEN BIO SCIENCE PVT LTD PBG	0.04	0.04
POLY MEDICURE LTD PBG		
PREMIUM SERUM & VACCINES PVT LTD PBG	13.48	
Q LINE BIOTECH PRIVATE LIMITED PBG	0.08	0.03
QM TRADERS PBG	2.22	
SAMARTH LIFE SCIENCE PBG		
SAM KEM PBG	0.19	
S D Biosensor Healthcare Pvt Ltd PBG	0.74	
SENSACORE MEDICAL INSTRUMENTATION PVT LTD PBG	0.12	
SERUM INSTITUTE OF INDIA PBG	1.50	
SHIWALI DRUG & SURGICALS PBG	0.20	
SHRI BAJRANG AYURVEDIC PBG	0.59	
SHRINIWAS POLYFABRIC AND PACKWELL PVT LTD PBG	14.71	14.71
Signova Healthcare PBG	0.10	
STERIMED MEDICA DEVICES LTD PBG	2.98	
STERIMED SURGICAL PBG	0.33	
SWISS GARNIER LIFE SCIENCE PBG	1.63	1.49
SYANA INDIA ASSOCIATES PBG	0.53	
SYSTRONICS PBG	0.65	
THEMIS MEDICARE LIMITED PBG	0.80	0.34
Theon Pharmaceuticals PBG	0.02	
THE PUNJAB HOMEOPATHIC PHARMACY PBG	1.33	
TITAN BIOTECH PBG	0.76	
TRUGEN PHARMACEUTICALS PVT LTD PBG	0.09	0.05
UNIJULES LIFESCIENCE LTD PBG	0.86	
Unisur Lifecare Private Limited PBG	0.73	0.73
UNISUR LIFECARE PVT LTD PBG	6.89	6.89



[Signature]
GM-CFO(F&A)
AMSCL

United Biotech PBG	0.08	
VADSP PHARMACEUTICAL PBG	3.52	
Vanguard Diagnostic PBG	0.47	
Vivimed Laboratories PBG	4.03	
WILCURE REMEDIES PVT LTD PBG	0.34	0.07
WOCKHARDT LTD PBG	0.15	
Total	132.22	35.04

Note No. 6(d)(d) Other current liabilities: Duties and Taxes

₹ in lakhs

Particulars	31st March 2024	As at 31st March 2023
TDS	1.62	1.38
GST Input/Output	110.74	
CGST 1%	24.07	24.87
IGST 2%	133.69	300.04
Professional Tax	0.09	0.07
SGST 1%	24.07	24.87
Forest Royalty	0.19	
10% DMFT on Forest Royalty	0.02	
10% MMDRRF on Forest Royalty	0.02	
Total	294.50	351.24

Note No. 6(e)(e) Other current liabilities: EMD Deposit

₹ in lakhs

Particulars	31st March 2024	As at 31st March 2023
3V SHOPPE EMD	1.98	
ABOTT DIAGNOSTICS SUSPENSE	2.00	2.00
ADS ENTERPRISE EMD	10.00	
AGAM PHARMACEUTICALS EMD	0.53	1.00
AYUSH INFOTECH EMD	0.32	1.65
BALAJI BAG MANUFACTURERS EMD		9.25
BEACON DIAGNOSTICS PVT LTD EMD	5.00	
Bharali Sports EMD		2.02
BHARAT PARENTERALS EMD		2.00
BIOMERIEUX INDIA PRIVATE LIMITED EMD	2.00	2.00
BMG Informatics EMD	0.26	1.69
CARE MEDICAL DEVICES LTD EMD		2.00
DSS Takara Bio India Pvt Ltd EMD	1.10	
EASTERN TECHNOLOGY GROUP EMD	0.91	0.58
ELITE COMPUTERS AND COMMUNICATIONS EMD		25.09
EURASIAN ASSOCIATES EMD	0.80	
Galaxy Medicare Ltd EMD	2.40	
HEALTHIUM MEDTECH EMD	7.25	
HIMACHAL PHARMACEUTICALS EMD	0.50	0.50
HOTEL SUNVIEW EMD	0.10	
INFOTECH SOLUTION EMD	2.76	
JAMNA HERBAL RESEARCH LTD EMD	0.04	
J K COMMERCIAL EMD		1.00
JYOTI PHARMACEUTICALS EMD		0.40
KERELA STATE HOMEOPATHIC CO-OPERATIVE LTD EMD	2.00	
MAA MANASHA PRINTER EMD	10.00	
MARUTI MEDITECH PVT LTD EMD		2.00
Mercantile Agents EMD		0.38
M/S A.K GROUP EMD	0.10	
Mylan Laboratories PBG	0.02	0.02
NORTH EAST ENTERPRISE EMD	2.40	
ONE TOUCH MEDICAL PRODUCTS PRIVATE EMD		2.00
OP COMMERCE ONLINE PRIVATE LTD EMD	10.00	
PIONEER AD CORPORATION EMD	0.06	
Poly Medicure EMD	1.35	



[Signature]
GM-CFO(F&A)
AMSCL

PROGRESSIVE ENTERPRISE EMD	11.11	1.11
QM TRADERS EMD	0.65	
ROYAL TRADE LINKS EMD		1.00
Senrysa Techno EMD	4.25	
SHRI BAJRANG AYURVEDIC EMD	0.27	
TIRUPATI MULTILAST EMD	10.30	
U D Scientific EMD	2.20	
VYGON INDIA PRIVATE LIMITED EMD		2.00
WEIGHING INDIA CORPORATION EMD		0.46
WHITE CLOUDS PVT LTD		1.00
VIVEK TRADING & ENGINEERING EMD	0.40	
Total	93.06	59.15

Note No. 6(f)(f) Other current liabilities: Employee & Others

₹ in lakhs

Particulars	31st March 2024	As at 31st March 2023
Avecon Healthcare (CL)	0.35	
Biswajit Deka (CL)	0.02	
Debahuti Sarma (CL)	0.02	
Indrajit Gohain (CL)	0.02	
Indrani Baishya Chakraborty (CL)	0.03	
JM Distributor (CL)	0.40	
Medini Mohan Saikia (CL)	0.16	
Nijara Boruah (CL)	0.02	
Parag Kr. Mahanta (CL)	0.04	
Pompy Roy (CL)	0.02	
Riya Bhardwaj (CL)	0.02	
Siddharth Bahadur Singh (CL)	0.19	
Sobhasmita Das (CL)	0.03	
Sumi Baishya (CL)	0.03	
Total	1.34	

**Note No. 8(a) (a) Loans and advances : Other loans and advances:
Unsecured, considered good(Head)**


₹ in lakhs

Particulars	As at 31st March 2024		As at 31st March 2023	
	Long-term	Short-term	Long-term	Short-term
Advance to BSNL				1.92
Advance to CDAC for EMMS Software		43.63		
Advance to NHM		13.72		13.72
Advance to DHS		11.94		
Advance to DHS (FW)		18.82		
Imprest Advance to Pabitra Debnath				0.50
Imprest Advance to Sandip Dutta				0.15
Total		88.11		16.29

**Note No. 11(a) Revenue from operations: Sale of services: Income from
Service Charges**

₹ in lakhs

Particulars	31st March 2024
Income from Service Charges - DHS FW	0.08
Income from Service Charges - ASACS	36.75
Income from Service Charges - AYUSH	8.24
Income from Service Charges - ECRP - II	0.56
Income from Service Charges - FDA	78.58
Income from Service Charges - 15th Finance Commission	78.27
Income from Service Charges - NHM ROP	620.02
Income from Service Charges - NHM State Budget	557.62
Income from Service Charges - Procurement of Ambulance	72.56
Income from Service Charges - ABDM	0.27
Total	1,452.96



GM-CFO(F&A)
AMSCL

Note No. 12(a) Other income: Other non-operating income: Other receipts

₹ in lakhs

Particulars	31st March 2024	31st March 2023
Forfeiture of EMD/BG (Penalty)	4.10	
Framework Agreement Fees	41.97	
Penalty on Late Delivery	0.37	
Miscellaneous Income		1.02
Total	46.44	1.02

Note No. 15(a) Other expenses: Other expenditure

₹ in lakhs

Particulars	31st March 2024	31st March 2023
Celebration Expenses	0.55	
Computer Accessories	0.58	0.02
DSC Making Charges	0.41	0.09
Electrical Fittings		0.24
Fee on GST		0.01
Housekeeping Expenses	4.03	3.02
Interest on GST		0.02
Interest & Fee on TDS	0.45	
Lodging Allowance	0.15	
Meeting & Interview Expenses	2.76	2.92
Multi-Tasking Staff Expenses	5.79	
Office Expenses	5.65	6.65
Office Stationery	0.38	
Petrol Oil & Lubricants	20.16	9.95
Repairs and Maintenance	2.49	1.13
Rounding Off		
Software Expenses	0.11	
Sponsorship Expenses	1.05	
TA/DA Expenses	2.98	
Training & Seminar	0.48	
Testing Charge for Bed sheet & Pillow		0.08
Vehicle Hiring Expenses	37.19	20.52
Website Expenses		4.18
Web Hosting & Website Security Expenses	0.34	
Total	85.55	48.83

Note No. 17 Earning Per Share

₹ in lakhs

Particulars	Before Extraordinary Items		After Extraordinary Items	
	31st March 2024	31st March 2023	31st March 2024	31st March 2023
Basic				
Profit after tax (A)	785.35	(196.22)	785.35	(196.22)
Weighted average number of shares outstanding (B)	8,54,000	8,54,000	8,54,000	8,54,000
Basic EPS (A / B)	91.96	(22.98)	91.96	(22.98)
Diluted				
Profit after tax (A)	785.35	(196.22)	785.35	(196.22)
Weighted average number of shares outstanding (B)	8,54,000	8,54,000	8,54,000	8,54,000
Diluted EPS (A / B)	91.96	(22.98)	91.96	(22.98)
Face value per share	100.00	100.00	100.00	100.00



[Signature]
GM-CFO(F&A)
AMSCL

Note number: Additional Regulatory Information

(1) Ratios:

Ratio	Numerator	Denominator	C.Y. Ratio	P.Y. Ratio	% Change	Reason for variance
(a) Current Ratio	Current Assets	Current Liabilities	1.05	1.01	3.96	
(b) Debt-Equity Ratio	Long Term Debt + Short Term Debt	Shareholder equity	0.00	0.00	0.00	
(c) Debt Service Coverage Ratio	Earning Before Interest, tax, Depreciation & Amortisation	Total principal + Interest on Borrowings			0.00	
(d) Return on Equity Ratio	Earning After Interest, tax, Depreciation & Amortisation	Average Shareholder's Equity	0.90	-0.32	-381.25	
(e) Inventory turnover ratio	Turnover	Average Inventory	0.00	0.00	0.00	
(f) Trade Receivables turnover ratio	Net Credit Sales	Average Trade Receivable	0.00	0.00	0.00	
(g) Trade payables turnover ratio	Net Credit Purchase	Average Trade Payable	0.00	0.00	0.00	
(h) Net capital turnover ratio	Total Sales	Average Working Capital	1.15	0.00	0.00	
(i) Net profit ratio	Net Profit	Net Sales	0.69	0.00	0.00	
(j) Return on Capital employed	Earning Before Interest & tax	Capital employed	0.62	-0.30	-306.67	
(k) Return on investment					0.00	




GM-CFO(F&A)
AMSCL

ACCOUNTING POLICIES & NOTES ON ACCOUNTS

Note No. : 18

NOTES FORMING PART OF FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST MARCH, 2024

A. ABOUT THE COMPANY

Assam Medical Services Corporation Limited is a public company incorporated on 22.06.2016. It is classified as a State Government Company and is registered at ROC Shillong. Their state of registration is Assam. Its authorized share capital is Rs 15,00,00,000.

B. SIGNIFICANT ACCOUNTING POLICIES

i. Basis for preparation of accounts

The financial statements of the Company have been prepared in accordance with the Generally Accepted Accounting Principles in India ("Indian GAAP") to comply with the Accounting Standards specified under Section 133 of the Companies Act, 2013, read with Rule 7 of the Companies (Accounts) Rules, 2014 and the relevant provisions of the Companies Act, 2013 ("the Act"), as applicable. The financial statements have been prepared on accrual basis under the historical cost convention. The accounting policies adopted in the preparation of the financial statements are consistent with those followed in the previous year. Current assets do not include elements which are not expected to be realized within one year and current liabilities do not include items which are due after one year.

ii. Use of Estimates

The preparation of financial statements require the management of the Company to make estimates and assumptions that affect the reported balances of assets and liabilities and disclosures relating to the contingent liabilities as at the date of the financial statements and reported amounts of income and expenses for the reporting period. The management believes that the estimates used in preparation of the financial statements are prudent and reasonable. Future results could differ from these estimates. Any revision to accounting estimates is recognised prospectively in the current and future periods. Example of such estimates includes provision for non - performing loans, provision for employee benefit plans and provision for income taxes.

iii. Property, Plant and Equipment (PPE)

PPE are initially recognized at cost. The initial cost of PPE comprises its purchase price, borrowing cost and any cost directly attributable to bringing the asset to its working condition for its intended use. PPE are stated at cost less accumulated depreciation and impairment losses, if any.

Subsequent expenditures related to an item of Tangible Assets are added to its book value only if they increase the future benefits from the existing assets beyond its previously assessed standard of performance. All other repairs and maintenance expenses are charged to profit or loss account during the reporting period in which they are incurred.

Depreciation on Fixed Assets is provided to the extent of depreciable amount on Written Down Value (WDV) method. Depreciation is provided based on useful life of the assets as prescribed in Schedule II of the Companies Act, 2013.

iv. Impairment of Assets

An asset is treated as impairment when the carrying cost of assets exceeded its recoverable value. An impairment loss is charged to the profit and loss statement in the year in which an asset is identified as impaired. The impairment loss recognized in prior accounting period is reserved if there has been a change in the estimate of recoverable amount.

Assam Medical Services Corporation Limited
Assessment Year: 2024-2025



v. Leases

Assets taken on lease under which all the risk and rewards of ownership are effectively retained by the lessor are classified as operating lease. Lease payments under operating leases are recognized as expenses on accrual basis with reference to the lease term and other considerations.

vi. Foreign Currency Transactions

Transactions denominated in Foreign Currency are recorded at the exchange rate prevailing on the date of the transaction. Liabilities and receivables in foreign currency are restated at the year-end exchange rates. All exchange rate differences arising from conversion in terms of the above are included in the statement of profit and loss.

vii. Revenue recognition

a. Income on Loan transactions

Income on loan transactions is accounted for by using the internal rate of return method. Consequently, a constant rate of return on net outstanding amount is accrued over the period of the contract, except that no income is recognised on non-performing assets as per the prudential norms for income recognition issued by the RBI for NBFCs. Interest income on such assets is recognised on receipt basis.

b. Income from Current and Long-term Investments

Income from dividend on shares of corporate bodies and units of mutual funds is accounted on accrual basis when the Company's right to receive dividend is established. Interest income on bonds and debentures is accounted on accrual basis.

viii. Provisions for Standard/Non Performing Assets and Doubtful Debts

The Company provides an allowance for loan receivables and debentures/bonds in the nature of advance based on the prudential norms issued by the RBI relating to income recognition, asset classification and provisioning for non-performing assets except for construction equipment, auto and personal loan portfolio where in addition to the provisioning as per RBI norms, the Company also provides for/ writes off the entire receivables, where any of the installments are overdue for a period exceeding 11 months.

ix. Investments

Non- Current Investments are valued at cost, determined on individual investment basis.

Current investments are stated at the lower of cost or market value, determined on an individual investment basis.

Interest, dividends, rentals, etc. form non-current investments and current investments are shown separately in the financial statements.

x. Employee Benefits

Employee benefits include provident fund, superannuation fund, employee state insurance scheme, gratuity fund, compensated absences, long service awards and post-employment medical benefits if any.

xi. Taxation

Income Tax

Current tax is the amount of tax payable on the taxable income for the year as determined in accordance with the applicable tax rates and the provision of the Income Tax Act, 1961 and the other applicable tax laws.



Deferred tax corresponds to the net effect of tax on all timing differences, which occur as a result of items being allowed for income tax purposes during a year different from when they were recognised in the financial statements.

xii. Operating Cycle

Based on the nature of products/activities of the company and the normal time between acquisition of assets and their realization in cash or cash equivalents, the company has determined its operating cycle as 12 months for the purpose of classification of its assets and liabilities as current and non-current.

xiii. Cash Flow Statement

Cash flows are reported using the indirect method, whereby profit / (loss) before extraordinary items and tax is adjusted for the effects of transactions of non-cash nature and any deferrals or accruals of past or future cash receipts or payments. The cash flows from operating, investing and financing activities of the Company are segregated based on the available information.

xiv. Earnings per share

Basic earnings per share is computed by dividing the profit / (loss) after tax (including the post tax effect of extraordinary items, if any) by the weighted average number of equity shares outstanding during the year. Diluted earnings per share is computed by dividing the profit / (loss) after tax (including the post tax effect of extraordinary items, if any) as adjusted for dividend, interest and other charges to expense or income (net of any attributable taxes) relating to the dilutive potential equity shares, by the weighted average number of equity shares considered for deriving basic earnings per share and the weighted average number of equity shares which could have been issued on the conversion of all dilutive potential equity shares. Potential equity shares are deemed to be dilutive only if their conversion to equity shares would decrease the net profit per share from continuing ordinary operations. Potential dilutive equity shares are deemed to be converted as at the beginning of the year, unless they have been issued at a later date. The dilutive potential equity shares are adjusted for the proceeds receivable had the shares been actually issued at fair value (i.e. average market value of the outstanding shares). Dilutive potential equity shares are determined independently for each period presented. The number of equity shares and potentially dilutive equity shares are adjusted for share splits / reverse share splits and bonus shares, as appropriate.

xv. Borrowing Costs

Borrowing cost that are attributable to the acquisition or construction or production of qualifying assets are capitalized as part of the cost of such assets till such time the assets is ready for intended use or sale. A qualifying asset is an asset that necessarily takes substantial period of time to get ready for its intended use or sale. Any other borrowing costs are recognized as an expense in the period in which they are incurred.

xvi. Provisions, Contingent Liabilities and Contingent Assets

Provision is recognized in the accounts when there is a present obligation as a result of past event(s) and it is probable that an outflow of resources will be required to settle the obligation and a reliable estimate can be made. Provisions are not discounted to their present value and are determined based on the best estimates required to settle the obligation at the reporting date. These estimates are reviewed at each reporting date and adjusted to reflect the current best estimates.

Contingent Liabilities is disclosed in Notes to the account for:

- Possible obligations which will be confirmed only by the future events not wholly within the control of the company or



- Present obligations arising from past events where it is not probable than an outflow of resources will be required to settle the obligation or a reliable estimate of the amount of the obligation cannot be made.

Contingent assets are not recognized in the financial statement since this may result in the recognition of the income that may never be realized.

for N.K. Choudhary & Associates

Chartered Accountants

FRN: 319216E



CA N.K. Choudhary

Partner

M. No.: 054570



Guwahati, Assam

August 31, 2024

Notes on Accounts

1. Sundry Creditors, Sundry Debtors, Loans & Advances and Unsecured Loans have been taken at their book value subject to confirmation and reconciliation.

2. Payments to Auditors:-

Auditors Remuneration	2023-2024	2022-2023
Statutory Audit Fees	25,000.00	25,000.00
Total	25,000.00	25,000.00

3. Loans and Advances are considered good in respect of which company does not hold any security other than the personal guarantee of persons.
4. Provisions of Accounting Standards (AS) - 17 issued by the Institute of Chartered Accountants of India on "Segment Reporting" are not been applicable to the Company.
5. Previous Year figures have been re-grouped or re-arranged wherever considered necessary.
6. Figures have been rounded off to the nearest rupees.
7. Figures in brackets indicate negative (-) figures.

8. Related Party Disclosures:

Name of Related Party	Designation	Nature of Transaction	Amount (in Rs.)
Premananda Hazarika	Senior Finance Controller	Remuneration	13,11,720/-
Anirban Talukdar	GM-Proc (QC, IT & Logistics)	Remuneration	13,11,720/-
Anirban Talukdar	GM-Proc (QC, IT & Logistics)	TA/DA	4,800/-
Dinesh Verma	GM-CFO (F&A)	Remuneration	8,14,887/-
Biswajit Deka	GM-CFO (F&A)	Remuneration	56,896/-
Biswajit Deka	GM-CFO (F&A)	TA/DA	1,800/-

for N.K. Choudhary & Associates

Chartered Accountants

FRN: 319216E


CA N.K. Choudhary

Partner

M. No.: 054570



Guwahati, Assam

August 31, 2024

Assam Medical Services Corporation Limited
Assessment Year: 2024-2025